Chronic Mid-Portion Achilles Tendinopathy (Investigational)
Investigational adjunct for chronic mid-portion (non-insertional) Achilles tendinopathy; eccentric loading remains evidence-based first-line.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for chronic mid-portion Achilles tendinopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). One small German report has described leech therapy here, but evidence is limited. Evidence-based first-line management of mid-portion Achilles tendinopathy is heavy slow eccentric loading (Alfredson protocol or modified versions) for at least 12 weeks, which is the single most evidence-supported intervention. Adjuncts may include shockwave therapy, platelet-rich plasma injection (mixed evidence), and surgical debridement for refractory cases.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Tendon rupture if leeches are placed inappropriately or if tendon is already significantly degenerated
- Worsening of tendinopathy pain in the first 1-2 weeks
- Wer dies nicht in Betracht ziehen sollte
- Patients who have not completed at least 12 weeks of structured heavy slow eccentric loading
- Patients with imaging-confirmed partial tendon tear (different management needed)
- Patients with insertional rather than mid-portion tendinopathy (different exercise protocol)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Have I completed 12+ weeks of Alfredson-style eccentric heel-drop exercises?
- Has ultrasound or MRI excluded a partial tendon tear?
- Has shockwave therapy or PRP been considered?
- What is the published evidence base for leeches in Achilles tendinopathy?
- What is the rupture risk in a degenerated tendon, and how is it minimized?
- How will success be measured — VISA-A score, return to sport, both?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden pop or sharp pain at the back of the heel with inability to push off (possible tendon rupture)
- Inability to walk normally or stand on tiptoe
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for tendinopathy — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace heavy slow eccentric loading, which is the best-supported first-line treatment.
- It does not heal tendon structure — collagen remodeling requires sustained mechanical loading.
- It does not address contributing factors (footwear, training errors, calf weakness).
- It does not have RCT evidence to support it as a primary therapy.
Sicherheits-Querverweise
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M76.60, M76.61, M76.62
- Safety tier
- medium
Evidence Summary
Mid-portion Achilles tendinopathy is a chronic degenerative tendinopathy distinct from insertional disease (separate registry entry). Evidence-based primary management is the Alfredson eccentric loading program (heavy slow resistance protocols also supported), with adjuncts including extracorporeal shock-wave therapy and selective use of PRP. No controlled clinical trial of peritendinous hirudotherapy for mid-portion Achilles tendinopathy has been published; any use is investigational and mechanistic only. Use as a primary therapy is inappropriate; eccentric loading must continue. The Achilles tendon has a tenuous mid-portion blood supply, so peri-tendon (not intratendinous) placement is essential.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Insertional tendinopathy (separate registry entry, different anatomy)
- Acute or partial Achilles tear (MRI confirmation needed; surgical or boot management)
- Fluoroquinolone-associated tendinopathy (taper drug; avoid invasive intervention until resolved)
- Discontinuation of eccentric loading program
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.